- Home
- NYC vs NNVC Comparison
NYC vs NNVC Comparison
Compare NYC & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYC
- NNVC
- Stock Information
- Founded
- NYC 2013
- NNVC 2005
- Country
- NYC United States
- NNVC United States
- Employees
- NYC N/A
- NNVC N/A
- Industry
- NYC Real Estate
- NNVC Biotechnology: Pharmaceutical Preparations
- Sector
- NYC Finance
- NNVC Health Care
- Exchange
- NYC Nasdaq
- NNVC Nasdaq
- Market Cap
- NYC 25.5M
- NNVC 22.5M
- IPO Year
- NYC N/A
- NNVC N/A
- Fundamental
- Price
- NYC $9.60
- NNVC $1.44
- Analyst Decision
- NYC
- NNVC
- Analyst Count
- NYC 0
- NNVC 0
- Target Price
- NYC N/A
- NNVC N/A
- AVG Volume (30 Days)
- NYC 3.4K
- NNVC 115.5K
- Earning Date
- NYC 11-11-2025
- NNVC 11-13-2025
- Dividend Yield
- NYC N/A
- NNVC N/A
- EPS Growth
- NYC N/A
- NNVC N/A
- EPS
- NYC N/A
- NNVC N/A
- Revenue
- NYC $54,865,000.00
- NNVC N/A
- Revenue This Year
- NYC $8.40
- NNVC N/A
- Revenue Next Year
- NYC $1.62
- NNVC N/A
- P/E Ratio
- NYC N/A
- NNVC N/A
- Revenue Growth
- NYC N/A
- NNVC N/A
- 52 Week Low
- NYC $7.89
- NNVC $0.94
- 52 Week High
- NYC $16.30
- NNVC $1.92
- Technical
- Relative Strength Index (RSI)
- NYC 36.10
- NNVC 47.56
- Support Level
- NYC $9.11
- NNVC $1.42
- Resistance Level
- NYC $10.50
- NNVC $1.47
- Average True Range (ATR)
- NYC 0.77
- NNVC 0.06
- MACD
- NYC -0.05
- NNVC 0.01
- Stochastic Oscillator
- NYC 22.98
- NNVC 61.27
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.